Eli Lilly and Company (NYSE:LLY) Holdings Lowered by American Financial Advisors LLC

American Financial Advisors LLC trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,028 shares of the company’s stock after selling 1,671 shares during the period. Eli Lilly and Company comprises about 1.6% of American Financial Advisors LLC’s holdings, making the stock its 22nd biggest holding. American Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $11,092,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Zhang Financial LLC lifted its stake in Eli Lilly and Company by 2.1% in the 4th quarter. Zhang Financial LLC now owns 1,672 shares of the company’s stock worth $975,000 after acquiring an additional 34 shares in the last quarter. Beaumont Financial Advisors LLC lifted its stake in Eli Lilly and Company by 2.1% in the 4th quarter. Beaumont Financial Advisors LLC now owns 6,356 shares of the company’s stock worth $3,705,000 after acquiring an additional 129 shares in the last quarter. Andrew Hill Investment Advisors Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter worth about $1,105,000. HTLF Bank purchased a new stake in Eli Lilly and Company in the 4th quarter worth about $444,000. Finally, Kellett Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 5.4% in the 4th quarter. Kellett Wealth Advisors LLC now owns 1,371 shares of the company’s stock worth $799,000 after acquiring an additional 70 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Bank of America increased their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research report on Wednesday, February 21st. Wells Fargo & Company upped their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Morgan Stanley upped their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $19.64 during mid-day trading on Friday, reaching $726.31. The stock had a trading volume of 3,503,501 shares, compared to its average volume of 3,073,465. The firm’s 50 day simple moving average is $764.24 and its 200 day simple moving average is $658.28. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a one year low of $369.76 and a one year high of $800.78. The firm has a market cap of $690.11 billion, a PE ratio of 125.67, a P/E/G ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter last year, the company earned $2.09 EPS. The company’s quarterly revenue was up 28.1% on a year-over-year basis. On average, analysts forecast that Eli Lilly and Company will post 12.52 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.